4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024991
PRESIDENT AND CEO sold 29,977 shares at an average $28.07 ($841,334)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kintz Samuel PRESIDENT AND CEO | 2024-10-08 | Sale 10b5-1 | −13,167 | $27.95 | $368,078 | 1,020,626 | I |
| Kintz Samuel PRESIDENT AND CEO | 2024-10-08 | Sale 10b5-1 | −100 | $28.51 | $2,851 | 1,020,526 | I |
| Kintz Samuel PRESIDENT AND CEO | 2024-10-09 | Sale 10b5-1 | −13,880 | $28.07 | $389,675 | 1,006,646 | I |
| Kintz Samuel PRESIDENT AND CEO | 2024-10-09 | Sale 10b5-1 | −2,830 | $28.53 | $80,730 | 1,003,816 | I |
| Open-market sales · 29,977 sh · avg $28.07 · $841,334 | |||||||
Loading xslF345X05/form4-10112024_121018.xml…